Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s products include ZN-c5 and ZN-c3. ZN-c5 is an oral selective estrogen receptor degrader, which is in a Phase I/II clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, and advanced or metastatic breast cancer. The Company engaged in initiating the Phase II monotherapy and combination portions of this Phase I/II trial. ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, is being evaluated in a Phase I/II clinical trial for the treatment of advanced solid tumors as a monotherapy and in a Phase Ib clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. It uses its Integrated Discovery Engine to identify targets and develop small molecule chemical entities with properties.